Switching to a Biosimilar for Your AMD Injections: How It Compares With Eylea
Biosimilar AMD Injections at a Glance
This is true of every aflibercept product. In the days after any eye injection, call your retina office the same day if you notice:
- Eye pain that is getting worse rather than settling.
- Vision that is dropping or blurring more.
- Redness that is spreading rather than fading.
- New sensitivity to light.
- A curtain or shadow across your sight.
- A sudden shower of new floaters, or flashing lights.
The drug label warns that an eye infection (clinical: endophthalmitis) can occur after an injection. So can a retina that pulls away from the back of the eye (clinical: retinal detachment). The label says to report the signs at once1. These events are rare. In 20 large reviews of 510,396 anti-VEGF injections, an eye infection came up about once in every 3,544 injections2. Most same-day calls end in good news. Call anyway. Care that starts early gives the eye its best chance.
The short answer, on the evidence so far, is yes. A biosimilar is a version of a biologic drug that is highly similar to one the FDA has already approved. It clears review only if there is no clinically meaningful difference in safety or in how well it works3. Your retina doctor may offer one in place of Eylea. The drug that goes into your eye does the same job.
One trial compared the two head to head in wet macular degeneration. At 8 weeks the biosimilar group had gained 6.7 letters on the eye chart. The Eylea group had gained 6.64. A switch is not a step down in your care. It changes which version of the same drug your clinic buys.
Rival versions of Eylea are now approved in the United States. In May 2024 the FDA approved Yesafili (aflibercept-jbvf) and Opuviz (aflibercept-yszy) as the first interchangeable biosimilars to Eylea, for wet age-related macular degeneration and several other retinal conditions5. Others have followed, including Pavblu (aflibercept-ayyh).
Practices and insurers move toward these products mainly for price. That is a legitimate reason, and worth asking about openly.
Almost nothing about your treatment changes. The active drug is aflibercept either way. The amount injected is the same, and the injection is given the same way.
What changes is the label on the vial, the maker, and the price your insurer is billed. If a switch is proposed, the useful questions are about coverage and timing, not about getting a weaker medicine.
What Eylea, Aflibercept, and Biosimilars Actually Are
Wet age-related macular degeneration starts when fragile new blood vessels grow under the center of your retina and leak fluid. A signal called VEGF drives the growth and leaking of those vessels, and anti-VEGF drugs such as aflibercept, the active drug in Eylea, cut the leaking by blocking it6.
Aflibercept is given as an intravitreal injection, meaning the drug is placed into the jelly that fills the back of the eye. It is approved for wet AMD, swelling after a retinal vein blockage, diabetic macular edema, and diabetic retinopathy1. It clears from the eye over weeks, so treatment is repeated.
A generic pill is a chemical copy that can be made identical to the original. Biologic drugs are grown in living cells, so an exact copy is not possible. That is why the word is biosimilar and not generic.
To be approved, a biosimilar must be shown to be highly similar to the drug it copies, with no clinically meaningful difference in safety, purity, or potency3. The FDA approved the aflibercept biosimilars after a review of scientific evidence that found them highly similar to Eylea, with no clinically meaningful differences in how well they work, in safety, or in immune response5. That bar is higher than a generic pill must clear.
Several aflibercept biosimilars have cleared FDA review since 2024. Yesafili and Opuviz were approved in May 2024, both carrying the FDA's interchangeable designation5. Pavblu (aflibercept-ayyh) is another FDA-approved biosimilar to Eylea, labeled for the same retinal conditions1.
Which one your practice stocks depends on supply contracts and on what your plan covers, and it can change from year to year. That is a business detail, not a judgment about your eye.
Eylea Compared With Its Aflibercept Biosimilars
The table below lines up the features patients ask about most. The medical details match, and the commercial details differ.
| What you compare | Eylea | Aflibercept biosimilar |
|---|---|---|
| Active drug | Aflibercept | Aflibercept, different maker |
| Dose for wet AMD | 2 mg into the eye | 2 mg into the eye |
| Usual schedule | Monthly at first, then spaced out | Monthly at first, then spaced out |
| Approved uses | Wet AMD and three other retinal conditions | The same list |
| Vision result in trials | The reference standard | Equivalent within the preset margin |
| Price to the system | Higher | Lower |
That does not make the two identical in every practical sense. Supply, coverage, and your treatment history still matter.
Interchangeable is a regulatory label, not a mark of extra quality. It means the FDA reviewed added evidence and concluded the product can be expected to give the same clinical result as the original, including in people who switch between the two3.
In a pharmacy, that designation can let a pharmacist substitute the product without contacting the prescriber, subject to state law3. Eye injections work differently. The drug is bought and given in your doctor's office, so the choice sits with your practice and your insurer. You can still ask what you are getting.
Be hopeful about savings, but not certain. Biosimilars may be available at a lower cost than the original biologic3. Across countries, anti-VEGF biosimilars have generally cost 30 to 80 dollars for every 100 dollars the original costs7.
Whether that reaches you is another question. In a study of 1.7 million outpatient claims for biologics given in clinics, biosimilar competition was not consistently linked to lower out-of-pocket costs for people with commercial insurance. Among claims that carried any out-of-pocket charge, the biosimilar ones averaged about 8 dollars lower for every 100 dollars than reference-drug claims, but biosimilar claims were more likely to carry a charge at all, and two years into competition average yearly out-of-pocket spending was about 12 dollars higher for every 1008. Ask your billing office for an estimate.
For most people on aflibercept for wet AMD, either product is reasonable, and coverage usually decides it. Staying on Eylea makes sense when your plan covers it well and a change would create delays.
A biosimilar makes sense when it lowers your cost, when your plan requires it, or when it is what your practice stocks. If your fluid has been hard to control lately, ask whether this is the right month to change anything.
What the Head-to-Head Research Shows About Switching
The strongest evidence comes from a trial built to detect a difference if one existed. It enrolled 449 people aged 50 and older with untreated wet AMD at 56 centers in 10 countries, assigning them at random to the aflibercept biosimilar SB15 or to Eylea. Neither the patients nor the examiners knew which4.
At week 8 the biosimilar group had gained 6.7 letters of vision and the Eylea group 6.6 letters. That gap of 0.1 letters sat well inside the range set before the study began, and side-effect rates were similar4. A tenth of a letter is below what anyone could notice.
The same trial tested switching directly, which is the part that matters if you are already on Eylea. At week 32, people were reassigned either to stay on what they were getting or to move from Eylea to the biosimilar9.
By week 56 the letter gains were 7.4 for those who stayed on the biosimilar, 7.0 for those who stayed on Eylea, and 7.9 for those who switched. The gap between switchers and non-switchers was 0.0 letters, and safety and immune response were comparable9. The switch did not cost anyone the ground they had gained.
Aflibercept treats more than one condition. A second trial tested a biosimilar in diabetic macular edema, the retinal swelling that diabetes can cause. It enrolled 355 adults with diabetic macular edema at 77 centers in the United States, Europe, Japan, and India. Its one pre-planned equivalence test came at week 8, where the two drugs differed by 0.04 letters of vision, inside the margin of 3 letters either way that the trial had set in advance. Follow-up then ran to week 52, and over that year vision, safety, blood levels of the drug, and immune response were reported as comparable between the two groups10. The formal equivalence finding belongs to that week-8 measurement, the later months are supporting follow-up rather than a second equivalence test, and this trial was run in diabetes, not in wet AMD.
A second condition, tested separately, pointing the same way is more reassuring than one trial alone, though a diabetes trial cannot stand in for evidence in wet AMD.
Honest limits belong on this page. The Academy has noted that the main aflibercept biosimilar trial followed people for only 56 weeks, and that longer studies and real-world experience are still needed11. Wet AMD is treated for years.
Early batches of Razumab, a ranibizumab biosimilar used in India, raised concerns about inflammation inside the eye, and those concerns were addressed by adjusting the manufacturing process7. That history argues for reporting symptoms promptly, not for refusing a well-regulated product.
Your Injection Visits and Dosing Schedule After a Switch
Your schedule is set by your retina, not by the brand on the vial. The labeled dose for wet AMD is 2 mg into the eye every 4 weeks for the first 12 weeks, then 2 mg every 8 weeks1. That is a starting framework, and your doctor may stretch or shorten the gaps based on your scans.
A switch does not reset your loading doses. You stay on the plan you were already following.
The visit itself is unchanged. Your eye is numbed and cleaned with an antiseptic. A small lid holder keeps you from blinking, and the injection takes a few seconds. Most people report pressure rather than sharp pain.
Eye pressure can rise briefly, and sharp increases have been seen within 60 minutes of an injection, so your team may check the pressure afterward1. Grittiness and a red spot on the white of the eye are common for a few days and settle on their own.
Wet AMD is a long-term treatment commitment. People typically need 7 or 8 injections in the first year, most need injections for the long term, and the interval is set by review rather than fixed6.
If a coverage change threatens to delay an appointment, tell the office. A gap in treatment is a bigger risk than which company made the aflibercept.
Side Effects, Serious Risks, and Who Should Not Get These Injections
Most side effects are local, mild, and short-lived. The label lists a red patch on the white of the eye in about 25 to 28 of every 100 people, eye pain in about 9 to 13 of every 100, and floaters in about 5 to 6 of every 1001.
| Common effect | How often it was reported |
|---|---|
| Red patch on the white of the eye. | About 25 to 28 of every 100 people. |
| Eye pain or soreness. | About 9 to 13 of every 100 people. |
| Cataract change over time. | About 7 to 8 of every 100 people. |
| Floaters. | About 5 to 6 of every 100 people. |
| Raised eye pressure. | About 5 to 8 of every 100 people. |
The same effects turn up with Eylea and with its biosimilars. A red patch looks alarming in the mirror, but it is usually harmless and fades over one to two weeks.
The serious risks belong to the injection itself, not to one brand. The label warns that endophthalmitis, an infection inside the eye, along with retinal detachment and retinal vasculitis, can occur in the days after an injection. Patients are told to report suggestive symptoms without delay1.
Infection is rare. Across 20 large series covering 510,396 anti-VEGF injections it occurred about once in every 3,544 injections, and other large analyses report rates nearer once in every 1,800 to 2,0002. Rare is not never, and knowing the signs matters because early treatment gives the eye its best chance. The label also notes a possible risk of artery clot events after eye injections of VEGF blockers1.
Some situations mean the injection is put off, and this applies equally to Eylea and to its biosimilars. The label rules out aflibercept in people with an infection in or around the eye, in people with active inflammation inside the eye, and in people with a known allergy to aflibercept or to any ingredient1.
Your ophthalmologist makes that call at the visit, not you at home. If you have a stye, pink eye, or a lid infection on injection day, phone ahead so the visit can be moved rather than simply skipped.
Anti-VEGF treatment aims to protect the vision you have, and many people regain some of it. In the biosimilar trials the average gain at one year was about 7 letters on the eye chart9, roughly a line and a half.
An average is not a promise. Results vary widely, depending on how much damage was there at the start. What is fair to say is that the choice between Eylea and a biosimilar is not what decides your outcome. Your schedule and the state of your macula matter far more.
Warning Signs to Call Your Retina Doctor About the Same Day
In the days after any eye injection, a few symptoms should prompt a call right away rather than a wait-and-see.
- Eye pain that is getting worse.
- Vision that is dropping or blurring more.
- Redness that is spreading rather than fading.
- New light sensitivity.
- A curtain or shadow across your sight.
- A sudden shower of new floaters or flashing lights.
The product label tells patients and caregivers to report signs of infection inside the eye or of retinal detachment without delay1. These events are uncommon. Calling the same day means your team can look at the eye instead of you waiting it out.
Other changes are worth reporting without being emergencies. Mild grittiness, a watery eye, or a red patch that is slowly fading can wait for office hours.
Straight lines that look bent, or a new gray patch in your central vision that stays put, deserve a prompt appointment even without pain. Those can mean fluid has returned and your schedule needs adjusting.
Retina practices expect these calls. They would rather hear about a false alarm than miss a real problem, so nobody will think you are overreacting.
Keep the after-hours number where you can find it, and note which product you got and when. That record helps your team advise you quickly.
Common Questions About Switching to a Biosimilar
You should not notice a difference in the visit or in how your eye feels after. The technique, the numbing, and the recovery are the same. In the randomized comparison, vision results and side-effect rates were similar between the biosimilar and Eylea4. The vial and the paperwork carry a different name, and your bill may look different. If a visit does feel different, say so.
You can always say what you prefer, and that talk belongs with your retina doctor. In practice the answer often turns on your insurance plan and on what your clinic can obtain. If staying on Eylea matters to you, ask whether an exception process exists, and ask what happens to your appointment timing meanwhile, since a treatment delay carries its own risk.
No. The drug, the dose, and the schedule are the same, so the strength of treatment does not change. The labeled wet AMD plan is 2 mg every 4 weeks for the first 12 weeks, then every 8 weeks, for a biosimilar just as for Eylea1. If your doctor is spacing out your injections, that comes from your scans and exam, not from which company supplied the drug.
Possibly, but it is not automatic. Biosimilars may be available at lower cost3, yet a large claims study found that biosimilar competition was not consistently linked to lower out-of-pocket costs for people with commercial insurance8. Your share depends on your plan design, your deductible, and how the drug is billed. Ask the billing office for an estimate before the switch, not after.
No, these are different things. Bevacizumab, sold as Avastin, is used off-label in the eye and has not been FDA-approved for an eye indication, which is why an ophthalmic version was still under review12. Retina specialists have used it that way for years because it is inexpensive. An aflibercept biosimilar is a version of Eylea approved for eye use. Cost modeling suggests an approved intraocular bevacizumab product could raise system and patient costs12.
No. A switch does not restart your loading phase or reset your interval. In the trial that tested this directly, people moved from Eylea to the biosimilar partway through, and their vision gains at one year matched those who never switched, a gap of 0.0 letters9. Keep your existing appointments. If you are told the clock restarts, ask your retina doctor to confirm, because extra injections carry their own risks.
More Questions About Biosimilar Eye Injections
Soreness after an injection is common with any aflibercept product, and usually reflects the procedure rather than the brand. Eye pain is listed on the label in about 9 to 13 of every 100 people1. The pattern is what matters. Soreness that eases over a day or two is expected. Pain that builds, with worsening vision or spreading redness, needs a same-day call. Report it with the product name so your team can track it.
No. Eylea HD is a separate 8 mg aflibercept product, given every 4 weeks for the first three doses and then once every 8 to 16 weeks13. The approved biosimilars match the 2 mg strength of the original Eylea5. So a 2 mg biosimilar is not a like-for-like swap for Eylea HD. Ask which product and strength you are on and whether your interval would change.
Ask, and ask for it in writing. The approved biosimilars carry their own names, such as Yesafili (aflibercept-jbvf) and Opuviz (aflibercept-yszy)5. That full name should appear in your visit summary and on your billing statement, and it is what pins down the exact product in your records. A short log of dates and product names helps if you change practices or need to report a problem.
Switching has been studied in one direction and looks reassuring, though evidence on repeated back-and-forth changes is thinner. In the phase 3 trial, people who moved from Eylea to the biosimilar had comparable vision, safety, and immune responses to those who did not switch9. The Academy still calls for longer-term and real-world data11. Raise it with your doctor rather than treating a change as routine.
Bring a short list to your next visit so the talk covers what matters.
- Which aflibercept product am I getting today, including the four-letter suffix?
- Is this a switch from last time, and what prompted it?
- Does my injection interval change with this product?
- What will my out-of-pocket cost be under my plan?
- If I want to stay on what I was getting, what would that involve?
- Which number do I call after hours if my eye hurts or my vision drops?
- How will we track which product I got at each visit?
- DailyMed, U.S. National Library of Medicine (FDA-approved product label, Amgen) (2024). PAVBLU (aflibercept-ayyh) injection, solution: full prescribing information.
- International Journal of Retina and Vitreous, pooled review of large retrospective injection series (2015). Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: a comprehensive review.
- U.S. Food and Drug Administration (2024). Biosimilars Basics for Patients.
- JAMA Ophthalmology, phase 3 double-masked randomized trial at 56 centers in 10 countries (2023). Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial.
- Healio Ophthalmology, reporting the FDA approval action (2024). FDA approves aflibercept biosimilars Yesafili, Opuviz.
- NCBI Bookshelf, evidence review of anti-VEGF therapy and guideline recommendations for wet AMD (2024). Anti-Vascular Endothelial Growth Factor Drugs for Age-Related Macular Degeneration.
- Eye (peer-reviewed multi-country review of anti-VEGF biosimilar experience) (2025). Biosimilars for anti-VEGF treatment of macular diseases: country and region reports.
- JAMA Health Forum, cohort study of 1.7 million outpatient claims from 190,364 commercially insured people (2024). Patient Out-of-Pocket Costs for Biologic Drugs After Biosimilar Competition.
- British Journal of Ophthalmology, week-56 and treatment-switch results of the SB15 phase 3 trial (2023). Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trial.
- JAMA Ophthalmology, double-masked randomized trial at 77 centers across the US, Europe, Japan and India (2024). Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema: The INSIGHT Randomized Clinical Trial.
- American Academy of Ophthalmology, Editors' Choice commentary on the SB15 phase 3 trial (2023). Aflibercept biosimilar shows efficacy and safety for treating neovascular AMD.
- Ophthalmology (journal of the American Academy of Ophthalmology), Medicare average-sales-price cost model (2023). The Biosimilar Paradox: How Anti-Vascular Endothelial Growth Factor Biosimilars Could Increase Patient and Overall Health Care Costs.
- DailyMed, U.S. National Library of Medicine (FDA-approved product label, Regeneron) (2025). EYLEA HD (aflibercept) injection, for intravitreal use: full prescribing information.